StockNews.com Upgrades Pulse Biosciences (NASDAQ:PLSE) to Sell

Pulse Biosciences (NASDAQ:PLSE) was upgraded by research analysts at StockNews.com to a “sell” rating in a report issued on Wednesday.

Pulse Biosciences Stock Performance

Shares of PLSE traded up $0.07 on Wednesday, reaching $20.37. The company’s stock had a trading volume of 179,185 shares, compared to its average volume of 202,376. The stock’s 50 day simple moving average is $17.18 and its two-hundred day simple moving average is $15.60. Pulse Biosciences has a 12-month low of $6.59 and a 12-month high of $22.69.

Pulse Biosciences (NASDAQ:PLSE) last posted its quarterly earnings data on Wednesday, October 30th. The company reported ($0.21) earnings per share (EPS) for the quarter. During the same period in the prior year, the firm earned ($0.19) EPS.

Hedge Funds Weigh In On Pulse Biosciences

Several hedge funds have recently modified their holdings of PLSE. Vanguard Group Inc. lifted its holdings in shares of Pulse Biosciences by 28.8% in the first quarter. Vanguard Group Inc. now owns 847,212 shares of the company’s stock worth $7,379,000 after buying an additional 189,227 shares in the last quarter. Price T Rowe Associates Inc. MD purchased a new position in shares of Pulse Biosciences in the first quarter worth $88,000. Cetera Advisors LLC purchased a new position in shares of Pulse Biosciences in the first quarter worth $109,000. Westside Investment Management Inc. lifted its holdings in shares of Pulse Biosciences by 97.8% in the second quarter. Westside Investment Management Inc. now owns 63,600 shares of the company’s stock worth $712,000 after buying an additional 31,440 shares in the last quarter. Finally, Bank of New York Mellon Corp lifted its holdings in shares of Pulse Biosciences by 23.4% in the second quarter. Bank of New York Mellon Corp now owns 50,914 shares of the company’s stock worth $570,000 after buying an additional 9,639 shares in the last quarter. Hedge funds and other institutional investors own 76.95% of the company’s stock.

About Pulse Biosciences

Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.